AT553122T - Antiangiogenic methods and compositions - Google Patents

Antiangiogenic methods and compositions

Info

Publication number
AT553122T
AT553122T AT06736663T AT06736663T AT553122T AT 553122 T AT553122 T AT 553122T AT 06736663 T AT06736663 T AT 06736663T AT 06736663 T AT06736663 T AT 06736663T AT 553122 T AT553122 T AT 553122T
Authority
AT
Austria
Prior art keywords
antiangiogenic
compositions
methods
Prior art date
Application number
AT06736663T
Other languages
German (de)
Inventor
H Steve Zhang
Philip D Gregory
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US65722405P priority Critical
Priority to US67758405P priority
Priority to US71532605P priority
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Priority to PCT/US2006/007382 priority patent/WO2006094106A2/en
Publication of AT553122T publication Critical patent/AT553122T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
AT06736663T 2005-02-28 2006-02-28 Antiangiogenic methods and compositions AT553122T (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US65722405P true 2005-02-28 2005-02-28
US67758405P true 2005-05-03 2005-05-03
US71532605P true 2005-09-08 2005-09-08
PCT/US2006/007382 WO2006094106A2 (en) 2005-02-28 2006-02-28 Anti-angiogenic methods and compositions

Publications (1)

Publication Number Publication Date
AT553122T true AT553122T (en) 2012-04-15

Family

ID=36829867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736663T AT553122T (en) 2005-02-28 2006-02-28 Antiangiogenic methods and compositions

Country Status (6)

Country Link
US (5) US7358085B2 (en)
EP (2) EP2314614B1 (en)
JP (1) JP4988606B2 (en)
AT (1) AT553122T (en)
CA (1) CA2599004C (en)
WO (1) WO2006094106A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
JP2007505837A (en) * 2003-09-15 2007-03-15 オードウェイ リサーチ インスティテュート Thyroid hormone analogs and methods of use in angiogenesis
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2006255183B2 (en) * 2005-06-08 2012-02-02 Centocor, Inc. A cellular therapy for ocular degeneration
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2023943A2 (en) * 2006-04-28 2009-02-18 Tulane University Health Sciences Center Methods for treating diabetes
KR101475303B1 (en) * 2006-07-12 2014-12-23 메소블라스트, 아이엔씨. Treatment of excessive neovascularization
US8319471B2 (en) 2006-12-06 2012-11-27 Solaredge, Ltd. Battery power delivery module
WO2008140507A2 (en) * 2006-12-22 2008-11-20 Clf Medical Technology Acceleration Program, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
KR101510778B1 (en) 2007-07-12 2015-04-10 상가모 바이오사이언스 인코포레이티드 Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression
WO2009035791A1 (en) * 2007-08-02 2009-03-19 Arresto Biosciences Lox and l0xl2 inhibitors and uses thereof
EP2250184A4 (en) * 2008-02-08 2011-05-04 Sangamo Biosciences Inc Treatment of chronic pain with zinc finger proteins
AU2009311697B2 (en) 2008-10-29 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
BRPI1007929A2 (en) * 2009-02-06 2015-09-01 Arresto Biosciences Inc "methods and compositions for treating neovascularization".
JP5932632B2 (en) * 2009-03-20 2016-06-15 サンガモ バイオサイエンシーズ, インコーポレイテッド Modification of CXCR4 using modified zinc finger protein
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
CA2765792C (en) 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders
EP2467162A4 (en) * 2009-08-21 2013-10-02 Gilead Biologics Inc Therapeutic methods and compositions
WO2011022709A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vitro screening assays
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
WO2011056073A2 (en) * 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CA2789022A1 (en) 2010-02-04 2011-08-11 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
KR101930711B1 (en) * 2010-10-12 2018-12-19 더 칠드런스 호스피탈 오브 필라델피아 Methods and compositions for treating hemophilia b
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US20120239681A1 (en) 2011-03-14 2012-09-20 Splunk Inc. Scalable interactive display of distributed data
US9370551B2 (en) 2011-07-27 2016-06-21 The Broad Institute, Inc. Compositions and methods of treating head and neck cancer
EP2820127B1 (en) * 2012-02-28 2018-09-26 Sigma Aldrich Co. LLC Targeted histone acetylation
JP6490426B2 (en) 2012-02-29 2019-03-27 サンガモ セラピューティクス, インコーポレイテッド Methods and compositions for treating Huntington's disease
SG11201500852WA (en) * 2012-08-29 2015-04-29 Sangamo Biosciences Inc Methods and compositions for treatment of a genetic condition
AU2015231353A1 (en) 2014-03-18 2016-10-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US9318974B2 (en) 2014-03-26 2016-04-19 Solaredge Technologies Ltd. Multi-level inverter with flying capacitor topology
CN109715551A (en) 2016-06-07 2019-05-03 纳米药业有限责任公司 With 3 integrin throstatics of α v β conjugation can not polymer pyrolysis
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653092A (en) * 1899-12-11 1900-07-03 Arthur F James Necktie-fastener.
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0476983B1 (en) 1990-09-21 2000-03-15 Merck & Co., Inc. Vascular endothelial cell growth factor II
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69229454T2 (en) 1991-03-28 2000-01-05 Merck & Co Inc Subunit C of vascular endothelial cell growth factor
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US5840686A (en) 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US6319687B1 (en) 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5503022A (en) 1993-01-25 1996-04-02 Barone; Larry A. Marine impeller tester
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
DE69534629D1 (en) 1994-01-18 2005-12-29 Scripps Research Inst Derivatives of zinc finger proteins and methods
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CN1267550C (en) 1994-03-08 2006-08-02 人体基因组科学有限公司 Vascular endothelial growth factor 2
AU3072099A (en) 1998-03-13 1999-09-27 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
NZ337634A (en) 1995-03-02 2001-06-29 Amrad Operations Pty method of inducing astroglial proliferation or promoting neuronal survival and/or proliferation by administering vascular endothelial growth factor (VEGF)
US20020026037A1 (en) 1995-06-06 2002-02-28 Jing-Shan Hu Vascular endothelial growth factor 3 antibodies
JPH11514976A (en) 1995-09-08 1999-12-21 ジェネンテク・インコーポレイテッド Vegf--related protein
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
AT306546T (en) 1996-08-23 2005-10-15 Ludwig Inst Cancer Res Recombinant vascular endothelial cell growth factor d (vegf-d)
US6131071A (en) * 1996-12-06 2000-10-10 Bp Amoco Corporation Spectral decomposition for seismic interpretation
WO1998024811A2 (en) 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
US6130071A (en) 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US5863736A (en) 1997-05-23 1999-01-26 Becton, Dickinson And Company Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
WO1999004806A1 (en) 1997-07-23 1999-02-04 Northwestern University Methods and compositions for inhibiting angiogenesis
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6007408A (en) 1997-08-21 1999-12-28 Micron Technology, Inc. Method and apparatus for endpointing mechanical and chemical-mechanical polishing of substrates
WO1999033485A1 (en) 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
DE69942334D1 (en) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly zinc finger proteins with improved linkers
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
CA2361615A1 (en) 1999-02-08 2000-08-10 Human Genome Sciences, Inc. The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
AT355368T (en) 2000-01-24 2006-03-15 Gendaq Ltd Nucleic acid binding polypeptide is identified by flexible linker-linked nucleic acid acid
AT353361T (en) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Targeted modification of the chromatin structure
AU2001255870B2 (en) 2000-04-28 2006-07-13 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
EP1276865B1 (en) 2000-04-28 2014-05-21 Sangamo BioSciences, Inc. Methods for binding an exogenous molecule to cellular chromatin
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US20060193830A1 (en) * 2002-03-20 2006-08-31 Hauswirth William W Raav vector compositions and methods for the treatment of choroidal neovascularization
CN1836048A (en) * 2003-06-10 2006-09-20 图尔金株式会社 Transducible DNA-binding proteins
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Also Published As

Publication number Publication date
US20080108556A1 (en) 2008-05-08
EP2314614B1 (en) 2015-11-25
US7795209B2 (en) 2010-09-14
US7358085B2 (en) 2008-04-15
US7893022B2 (en) 2011-02-22
JP4988606B2 (en) 2012-08-01
US20060210539A1 (en) 2006-09-21
US7732196B2 (en) 2010-06-08
CA2599004C (en) 2015-05-26
EP1869075A2 (en) 2007-12-26
US20080187523A1 (en) 2008-08-07
EP2314614A1 (en) 2011-04-27
WO2006094106A3 (en) 2007-02-15
CA2599004A1 (en) 2006-09-08
WO2006094106A2 (en) 2006-09-08
US20080118469A1 (en) 2008-05-22
EP1869075B1 (en) 2012-04-11
JP2008531056A (en) 2008-08-14
US8012946B1 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
DK1765327T3 (en) Compounds, compositions and methods
DK1988307T3 (en) Reducers
AT408603T (en) pyrazolylcarboxanilides
AT446040T (en) Handstaubsauger
AT523504T (en) 1-thio-D-GLUCITOLDERIVATE
AT487422T (en) Nickness lanzette
AT498360T (en) Ösennahtanker
AT423121T (en) Diphenylimidazopyrimidin and imidazolamines as b-secretase inhibitors
AT441315T (en) Equipment fan
AT552163T (en) Straddle-VEHICLE
AT527526T (en) Photonenzählvorrichtung
AT489405T (en) Hybridcopolymere
AT539711T (en) Hüftpfannenpositionierung
DE502006003957D1 (en) NANO-thermoelectrics
DE602005020609D1 (en) Tem
RU2007128652A (en) Tights
DE502006005443D1 (en) Fan
DK3090748T3 (en) Compositions concerning nukleotid and oligonukleotid products
AT485852T (en) Oberflächeninjizierungsvorrichtung
AT437205T (en) Styrylsulfidfarbstoffe
AT427965T (en) Antikírper against 25-hydroxyvitamine d
DE602005021126D1 (en) New composition against xerostomy
DK2004786T3 (en) Cleaning Compositions and Methods
DE502007001811D1 (en) Stanzniet and matrize
EP1899480A4 (en) Compositions and methods for treating inflammatory conditions